Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Poster Session Abstracts

Abstract P3-10-01: Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer

C Cleeland, R von Moos, M Walker, Y Wang, J Gao, A Liede, J Arellano, A Balakumaran and Y Qian
C Cleeland
University of Texas MD Anderson Cancer Center, Houston, TX; Kantonsspital Graubünden, Chur, Switzerland; ACORN Research LLC, Memphis, TN; IMS Health, Plymouth Meeting, PA; Amgen Inc., Thousand Oaks, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R von Moos
University of Texas MD Anderson Cancer Center, Houston, TX; Kantonsspital Graubünden, Chur, Switzerland; ACORN Research LLC, Memphis, TN; IMS Health, Plymouth Meeting, PA; Amgen Inc., Thousand Oaks, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Walker
University of Texas MD Anderson Cancer Center, Houston, TX; Kantonsspital Graubünden, Chur, Switzerland; ACORN Research LLC, Memphis, TN; IMS Health, Plymouth Meeting, PA; Amgen Inc., Thousand Oaks, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y Wang
University of Texas MD Anderson Cancer Center, Houston, TX; Kantonsspital Graubünden, Chur, Switzerland; ACORN Research LLC, Memphis, TN; IMS Health, Plymouth Meeting, PA; Amgen Inc., Thousand Oaks, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J Gao
University of Texas MD Anderson Cancer Center, Houston, TX; Kantonsspital Graubünden, Chur, Switzerland; ACORN Research LLC, Memphis, TN; IMS Health, Plymouth Meeting, PA; Amgen Inc., Thousand Oaks, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Liede
University of Texas MD Anderson Cancer Center, Houston, TX; Kantonsspital Graubünden, Chur, Switzerland; ACORN Research LLC, Memphis, TN; IMS Health, Plymouth Meeting, PA; Amgen Inc., Thousand Oaks, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J Arellano
University of Texas MD Anderson Cancer Center, Houston, TX; Kantonsspital Graubünden, Chur, Switzerland; ACORN Research LLC, Memphis, TN; IMS Health, Plymouth Meeting, PA; Amgen Inc., Thousand Oaks, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Balakumaran
University of Texas MD Anderson Cancer Center, Houston, TX; Kantonsspital Graubünden, Chur, Switzerland; ACORN Research LLC, Memphis, TN; IMS Health, Plymouth Meeting, PA; Amgen Inc., Thousand Oaks, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y Qian
University of Texas MD Anderson Cancer Center, Houston, TX; Kantonsspital Graubünden, Chur, Switzerland; ACORN Research LLC, Memphis, TN; IMS Health, Plymouth Meeting, PA; Amgen Inc., Thousand Oaks, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/0008-5472.SABCS13-P3-10-01 Published December 2013
  • Article
  • Figures & Data
  • Info & Metrics
Loading
Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX

Abstract

Background: Bone is the most common site of distant metastasis in advanced breast cancer patients (pts). Development of bone metastases (mets) is associated with substantial morbidity including skeletal complications, decreased quality of life, increased pain, and shortened lifespan. Pt burden of symptoms associated with bone mets has been assessed in tumor types other than breast or in metastatic disease not specific to bone. This study characterizes patterns of pt-reported symptoms over time among breast cancer pts with bone mets.

Methods: The Oncology Services Comprehensive Electronic Records (OSCER) database was used to retrospectively identify women with breast cancer who developed bone mets during their care and had ≥1 ACORN Patient Care Monitor (PCM) assessment. The PCM summarizes symptoms on an 11-point scale (0 = not a problem to 10 = as bad as possible). Moderate/severe symptoms were defined by a PCM score ≥4. PCM items relevant to metastatic disease (fatigue, physical pain, trouble sleeping, numbness/tingling, anxious, loss of interest in others) were assessed. A generalized linear mixed model was used to evaluate symptom progression before and after bone mets diagnosis (dx). Kaplan-Meier methods were used to estimate time to development of and proportion of pts with moderate/severe symptoms after bone mets dx.

Results: 1105 pts with breast cancer and bone mets were included. In general, the proportion of pts with moderate/severe symptom burden increased in the months (mos) before bone mets dx (Table 1). The odds (risk) of pts experiencing moderate/severe symptom burden increased in the mos leading up to bone mets dx, with a 9% increase per mo for both fatigue and physical pain, and a 19% increase per mo for numbness/tingling (P<0.001 for all). Non-significant changes were observed in the risk of pts experiencing trouble sleeping (3%), anxiousness (0%), or loss of interest in others (16%). After bone mets dx, the cumulative proportion of pts with moderate/severe symptom burden increased with time (Table 2). Median time to moderate/severe symptoms after bone mets dx was 1.4 mos for fatigue, 1.9 mos for physical pain, 3.9 mos for trouble sleeping, 9.3 mos for numbness/tingling, 20.6 mos for anxious, and was not reached for loss of interest in others.

View this table:
  • View inline
  • View popup

Table 1. Unadjusted proportion of pts with moderate/severe symptom burden before or at time of bone mets dx

Conclusions: These data from a large number of breast cancer pts treated at community oncology practices show that pts experience increasing symptom burden for a substantial period of time before bone mets dx. Most pts continue to experience burdensome symptoms after bone mets dx. These findings reinforce the need for multiple symptoms to be proactively monitored and managed in these pts.

View this table:
  • View inline
  • View popup

Table 2. KM estimate: cumulative proportion of pts with moderate/severe symptom burden after bone mets dx

Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-10-01.

Previous
Back to top
Cancer Research: 73 (24 Supplement)
December 2013
Volume 73, Issue 24 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract P3-10-01: Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract P3-10-01: Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer
C Cleeland, R von Moos, M Walker, Y Wang, J Gao, A Liede, J Arellano, A Balakumaran and Y Qian
Cancer Res December 15 2013 (73) (24 Supplement) P3-10-01; DOI: 10.1158/0008-5472.SABCS13-P3-10-01

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract P3-10-01: Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer
C Cleeland, R von Moos, M Walker, Y Wang, J Gao, A Liede, J Arellano, A Balakumaran and Y Qian
Cancer Res December 15 2013 (73) (24 Supplement) P3-10-01; DOI: 10.1158/0008-5472.SABCS13-P3-10-01
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Poster Session Abstracts

  • Abstract P6-14-05: Phase 2 study evaluating the efficacy and safety of eribulin mesylate administered biweekly for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer
  • Abstract P6-08-07: Decline in compliance to breast cancer screening in France: Results of the 5th EDIFICE survey
  • Abstract P6-08-04: National trends in mastectomy for operable breast cancers treated with neoadjuvant chemotherapy
Show more 3

Poster Session 3: Psychosocial, Quality of Life, and Educational Aspects: Palliation and Support - Pain Management

  • Abstract P3-10-02: The BOMET-QOL questionnaire in patients with breast cancer and bone metastasis: The prospective MABOMET study from the Spanish breast cancer research group (GEICAM)
  • Abstract P3-10-04: Prevalence of pain and barriers to pain management in breast cancer survivors in Vietnam
  • Abstract P3-10-03: A simple intervention to relieve chronic neuropathic post-mastectomy pain
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement